Patients′ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial

被引：0
|
作者：
Reck, M. [1 ]
Granados, A. L. O. Ortega [2 ]
de Marinis, F. [3 ]
Shen, Q. [4 ]
Boklage, S. H. [4 ]
Dabrowski, C. [5 ]
Cho, L. [6 ]
Meyers, O. [7 ]
机构：
[1] Lungen Clin, Dept Thorac Oncol, Airway Res Ctr North, Ctr Lung Res, Grosshansdorf, Germany
[2] Hosp Univ Jaen, Dept Med Oncol, Jaen, Spain
[3] Ist Europeo Oncol IRCCS, Div Thorac Oncol, Milan, Italy
[4] GSK, Oncol Value Evidence & Outcomes, Collegeville, PA USA
[5] GSK, Global Clin Safety, Collegeville, PA USA
[6] GSK, Global Med Affairs, Collegeville, PA USA
[7] GSK, Patient Ctr Outcomes Value Evidence & Outcomes, Collegeville, PA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2499
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1468P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Patients' perspective on tolerability of dostarlimab in NSCLC: patient-reported outcomes from the Phase II PERLA trial
    Reck, Martin
    Granados, Ana Laura Ortega
    de Marinis, Filippo
    Shen, Qin
    Boklage, Susan
    Dabrowski, Christine
    Cho, Lillian
    Meyers, Oren
    Griesinger, Frank
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 130 - 130
  • [2] Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the randomized Phase II PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab
    Reck, Martin
    Granados, Ana Laura Ortega
    de Marinis, Filippo
    Meyers, Oren
    Shen, Qin
    Cho, Lillian
    Stjepanovic, Neda
    Boklage, Susan
    EUROPEAN JOURNAL OF CANCER, 2024, 212
  • [3] Patient-Reported Outcomes (PROs) in Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC): PERLA Trial Comparing First-Line Chemotherapy Plus Dostarlimab or Pembrolizumab
    Reck, Martin
    Granados, Ana Laura Ortega
    de Marinis, Filippo
    Meyers, Oren
    Shen, Qin
    Cho, Lillian
    Boklage, Susan
    Gouldin, Winston
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E26 - E27
  • [4] The patient's perspective on treatment with dacomitinib: patient-reported outcomes from the Phase III trial ARCHER 1050
    Paty, Jean
    Sandin, Rickard
    Reisman, Arlene
    Wu, Yi-Long
    Migliorino, Maria Rita
    Zhou, Xiangdong
    Cheng, Ying
    Lee, Ki Hyeong
    Nakagawa, Kazuhiko
    Niho, Seiji
    Corral, Jesus
    Pluzanski, Adam
    Linke, Rolf
    Meyers, Oren
    Mok, Tony S.
    FUTURE ONCOLOGY, 2021, 17 (07) : 783 - 794
  • [5] Patient-reported outcomes in patients with metastatic non-squamous non-small cell lung cancer from the PERLA trial comparing first-line chemotherapy plus dostarlimab or pembrolizumab
    Reck, Martin
    Granados, Ana Laura Ortega
    de Marinis, Filippo
    Meyers, Oren
    Boklage, Susan
    Shen, Qin
    Cho, Lillian
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Patient-reported outcomes in a phase II study of alectinib
    Ohe, Yuichiro
    ESMO OPEN, 2018, 3 (05)
  • [7] PATIENT-REPORTED OUTCOMES IN THE GARNET TRIAL IN PATIENTS WITH ADVANCED OR RECURRENT MISMATCH REPAIR DEFICIENT SOLID TUMORS TREATED WITH DOSTARLIMAB
    Kristeleit, Rebecca
    Mathews, Cara
    Redondo, Andres
    Pennington, Kathryn
    Boklage, Susan
    Brown, Jubilee
    ONCOLOGY NURSING FORUM, 2022, 49 (02) : E57 - E58
  • [8] Incorporating patient-reported outcomes in a phase I clinical trial
    Qin, Rui
    Dueck, Amylou C.
    Satele, Daniel
    Molina, Julian
    Erlichman, Charles
    Basch, Ethan
    Sloan, Jeff
    QUALITY OF LIFE RESEARCH, 2013, 22
  • [9] Patient-Reported Outcomes for Tolerability Assessment in Phase I Cancer Clinical Trials
    Basch, Ethan
    Yap, Christina
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (08): : 943 - 944
  • [10] Patient-reported outcomes for subarachnoid hemorrhage Capturing the patients' perspective
    Turner, Grace M.
    Mant, Jonathan
    NEUROLOGY, 2019, 92 (06) : 259 - 261
12345